|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2006-6-1
|
|
pubmed:abstractText |
The optimal treatment for primary non-Hodgkin's lymphoma (NHL) of the nasal cavity remains controversial. This study was to analyze the initial response rate of radiotherapy and chemotherapy, and the influence of different treatment modalities on prognosis.
|
|
pubmed:language |
chi
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0253-3766
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
28
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
58-61
|
|
pubmed:meshHeading |
pubmed-meshheading:16737624-Adult,
pubmed-meshheading:16737624-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16737624-Combined Modality Therapy,
pubmed-meshheading:16737624-Cyclophosphamide,
pubmed-meshheading:16737624-Disease-Free Survival,
pubmed-meshheading:16737624-Doxorubicin,
pubmed-meshheading:16737624-Female,
pubmed-meshheading:16737624-Follow-Up Studies,
pubmed-meshheading:16737624-Humans,
pubmed-meshheading:16737624-Killer Cells, Natural,
pubmed-meshheading:16737624-Lymphoma, Non-Hodgkin,
pubmed-meshheading:16737624-Male,
pubmed-meshheading:16737624-Nasal Cavity,
pubmed-meshheading:16737624-Neoplasm Recurrence, Local,
pubmed-meshheading:16737624-Neoplasm Staging,
pubmed-meshheading:16737624-Nose Neoplasms,
pubmed-meshheading:16737624-Particle Accelerators,
pubmed-meshheading:16737624-Prednisone,
pubmed-meshheading:16737624-Radiotherapy, High-Energy,
pubmed-meshheading:16737624-Remission Induction,
pubmed-meshheading:16737624-Retrospective Studies,
pubmed-meshheading:16737624-Survival Rate,
pubmed-meshheading:16737624-Treatment Outcome,
pubmed-meshheading:16737624-Vincristine
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
[Treatment option and outcome for patients with primary non-Hodgkin's lymphoma of the nasal cavity].
|
|
pubmed:affiliation |
Department of Radiation Oncology, Cancer Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
|
|
pubmed:publicationType |
Journal Article,
English Abstract
|
